David Shapiro
Directeur/Membre du Conseil chez GALECTO, INC.
Fortune : - $ au 30/04/2024
Postes actifs de David Shapiro
Sociétés | Poste | Début | Fin |
---|---|---|---|
GALECTO, INC. | Directeur/Membre du Conseil | 19/05/2020 | - |
Independent Dir/Board Member | 19/05/2020 | - | |
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Integrated Quality Resources, Inc. | Directeur Général | 01/01/1998 | - |
Fondateur | 01/01/1998 | - | |
President | 01/01/1998 | - | |
Yaqrit Discovery Ltd.
Yaqrit Discovery Ltd. Hospital/Nursing ManagementHealth Services Yaqrit Discovery Ltd is a British company that focuses on advancing the treatment of liver disease. The company is based in Ledbury, UK and has subsidiaries in the United Kingdom. Green. Yaqrit Discovery Ltd was founded in 2001 by Rajiv Jalan and the CEO is Daniel J. | Directeur/Membre du Conseil | - | - |
Historique de carrière de David Shapiro
Anciens postes connus de David Shapiro
Sociétés | Poste | Début | Fin |
---|---|---|---|
ORGANOVO HOLDINGS, INC. | Directeur/Membre du Conseil | 04/12/2018 | 14/07/2020 |
Independent Dir/Board Member | 04/12/2018 | 14/07/2020 | |
INTERCEPT PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2007 | 01/05/2019 |
Arcturus Therapeutics Ltd.
Arcturus Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/11/2017 | 27/05/2018 |
Independent Dir/Board Member | 01/11/2017 | 27/05/2018 | |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Directeur/Membre du Conseil | 12/08/2009 | 09/03/2011 |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/01/2000 | - |
░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de David Shapiro
University of Dundee School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 13 |
Royaume-Uni | 4 |
Opérationnelle
Director/Board Member | 7 |
Corporate Officer/Principal | 5 |
Independent Dir/Board Member | 3 |
Sectorielle
Health Technology | 9 |
Consumer Services | 3 |
Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
ORGANOVO HOLDINGS, INC. | Health Technology |
GALECTO, INC. | Health Technology |
Entreprise privées | 10 |
---|---|
American Academy of Pharmaceutical Physicians | |
Scripps Clinic Medical Group, Inc. | |
Gensia Pharmaceuticals, Inc.
Gensia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gensia Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products for cardiovascular diseases. The company is based in San Diego, CA and has subsidiaries in the United States. The company was founded by Robert L. Engler, Paul K. Laikind. | Health Technology |
Organon Pharma (UK) Ltd.
Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Health Technology |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Health Technology |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
Integrated Quality Resources, Inc. | |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
Arcturus Therapeutics Ltd.
Arcturus Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA. | Health Technology |
Yaqrit Discovery Ltd.
Yaqrit Discovery Ltd. Hospital/Nursing ManagementHealth Services Yaqrit Discovery Ltd is a British company that focuses on advancing the treatment of liver disease. The company is based in Ledbury, UK and has subsidiaries in the United Kingdom. Green. Yaqrit Discovery Ltd was founded in 2001 by Rajiv Jalan and the CEO is Daniel J. | Health Services |
- Bourse
- Insiders
- David Shapiro
- Expérience